WFRF:(Junlen Henna Riikka)
Search: WFRF:(Junlen Henna Riikka) > Chemotherapeutic in...
- 2 of 2
- Previous record
- Next record
- To hitlist
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
-
- Melén, Christopher M. (author)
- Karolinska Institutet
-
- Enblad, Gunilla (author)
- Uppsala universitet,Experimentell och klinisk onkologi,Uppsala University Hospital
-
- Sonnevi, Kristina (author)
- Karolinska Institutet
- show more...
- show less...
- (creator_code:org_t)
- 2016-10-28
- 2016
- English.
- In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 175:4, s. 614-622
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Young patients with diffuse large B-cell lymphoma (DLBCL) are variably treated with rituximab combined with cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP), CHOP-etoposide (R-CHOEP), and anthracycline-based regimens with the addition of high-dose cytarabine/methotrexate (R-HDA/M). Using the nationwide, population-based Swedish Lymphoma Registry, we evaluated outcome, by treatment and Healthcare Region, in all 751 DLBCL patients aged 60years without central nervous involvement, diagnosed in Sweden between 2007 and 2012. Overall survival was estimated using multivariate Cox analysis. In patients with age-adjusted international prognostic index (aaIPI)2, the 5-year overall survival (OS) was 70%, 76% and 85% after R-CHOP, R-CHOEP and R-HDA/M, respectively (P=0002); the corresponding estimates were 40%, 55%, and 92% in aaIPI=3 (P=0014). There were large therapeutic differences between Sweden's six Healthcare Regions for aaIPI2: three were Moderate (more R-CHOP) and three Intensive (more R-CHOEP and R-HDA/M). Patients with aaIPI2 who were treated in the Intensive Regions, showed better OS (P<000005), particularly those with aaIPI=3 (5-year OS, 62% vs. 30%; P<000005). There were no regional differences in therapy or survival in patients with aaIPI<2. We conclude that in younger high-risk patients, survival appears superior after more intensive therapy than R-CHOP.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Diffuse large B-cell lymphoma
- intensive chemotherapy
- young
- aaIPI
- cytarabine
- aaIPI
- cytarabine
- Diffuse large B-cell lymphoma
- intensive chemotherapy
- young
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- British Journal of Haematology (Search for host publication in LIBRIS)
To the university's database
- 2 of 2
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Melén, Christoph ...
- Enblad, Gunilla
- Sonnevi, Kristin ...
- Junlen, Henna Ri ...
- Smedby, Karin E.
- Jerkeman, Mats
- show more...
- Wahlin, Björn En ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- British Journal ...
- By the university
- Uppsala University
- Lund University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
